133 related articles for article (PubMed ID: 37923962)
1. Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system.
Kantor ED; O'Connell K; Ergas IJ; Valice E; Roh JM; Bhimani J; Heon N; Griggs JJ; Lee J; Bowles EJ; Rivera DR; Kolevska T; Bandera EV; Kushi LH
Breast Cancer Res Treat; 2024 Feb; 203(3):565-574. PubMed ID: 37923962
[TBL] [Abstract][Full Text] [Related]
2. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.
Carroll JP; Protani MM; Nguyen L; Cheng ME; Fay M; Saleem M; Pillay PS; Walpole E; Martin JH
Med Oncol; 2014 Apr; 31(4):881. PubMed ID: 24549982
[TBL] [Abstract][Full Text] [Related]
4. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Furlanetto J; Eiermann W; Marmé F; Reimer T; Reinisch M; Schmatloch S; Stickeler E; Thomssen C; Untch M; Denkert C; von Minckwitz G; Lederer B; Nekljudova V; Weber K; Loibl S; Möbus V
Ann Oncol; 2016 Nov; 27(11):2053-2059. PubMed ID: 27502721
[TBL] [Abstract][Full Text] [Related]
5. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.
Rosner GL; Hargis JB; Hollis DR; Budman DR; Weiss RB; Henderson IC; Schilsky RL
J Clin Oncol; 1996 Nov; 14(11):3000-8. PubMed ID: 8918498
[TBL] [Abstract][Full Text] [Related]
6. Undertreatment of obese women receiving breast cancer chemotherapy.
Griggs JJ; Sorbero ME; Lyman GH
Arch Intern Med; 2005 Jun; 165(11):1267-73. PubMed ID: 15956006
[TBL] [Abstract][Full Text] [Related]
7. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
[TBL] [Abstract][Full Text] [Related]
8. Are medical oncologists biased in their treatment of the large woman with breast cancer?
Madarnas Y; Sawka CA; Franssen E; Bjarnason GA
Breast Cancer Res Treat; 2001 Mar; 66(2):123-33. PubMed ID: 11437098
[TBL] [Abstract][Full Text] [Related]
9. Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer.
Cespedes Feliciano EM; Chen WY; Lee V; Albers KB; Prado CM; Alexeeff S; Xiao J; Shachar SS; Caan BJ
JAMA Oncol; 2020 Feb; 6(2):264-270. PubMed ID: 31804676
[TBL] [Abstract][Full Text] [Related]
10. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.
Cespedes Feliciano EM; Lee VS; Prado CM; Meyerhardt JA; Alexeeff S; Kroenke CH; Xiao J; Castillo AL; Caan BJ
Cancer; 2017 Dec; 123(24):4868-4877. PubMed ID: 28881381
[TBL] [Abstract][Full Text] [Related]
11. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
[TBL] [Abstract][Full Text] [Related]
12. Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study.
Gadisa DA; Assefa M; Wang SH; Yimer G
J Oncol Pharm Pract; 2020 Dec; 26(8):1912-1920. PubMed ID: 32122234
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Dose Dense Chemotherapy in Patients With Obesity: Short-Term Toxicities and Breast Cancer Outcome.
Lomma C; Chih H; Chan A
Clin Breast Cancer; 2023 Jul; 23(5):491-499. PubMed ID: 37169686
[TBL] [Abstract][Full Text] [Related]
14. Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System.
Rashid N; Koh HA; Baca HC; Li Z; Malecha S; Abidoye O; Masaquel A
J Manag Care Spec Pharm; 2015 Oct; 21(10):863-71. PubMed ID: 26402387
[TBL] [Abstract][Full Text] [Related]
15. Impact of body mass index on survival in women receiving chemotherapy for early breast cancer.
Pezo RC; Chan KKW; Mata DGMM; Menjak I; Eisen A; Trudeau M
Breast Cancer Res Treat; 2022 Nov; 196(2):329-339. PubMed ID: 36114940
[TBL] [Abstract][Full Text] [Related]
16. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
[TBL] [Abstract][Full Text] [Related]
18. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice.
Weycker D; Barron R; Edelsberg J; Kartashov A; Lyman GH
Breast Cancer Res Treat; 2012 May; 133(1):301-10. PubMed ID: 22270932
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Liu MC; Demetri GD; Berry DA; Norton L; Broadwater G; Robert NJ; Duggan D; Hayes DF; Henderson IC; Lyss A; Hopkins J; Kaufman PA; Marcom PK; Younger J; Lin N; Tkaczuk K; Winer EP; Hudis CA;
Cancer Treat Rev; 2008 May; 34(3):223-30. PubMed ID: 18234424
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
Schwartz J; Toste B; Dizon DS
Gynecol Oncol; 2009 Jul; 114(1):53-6. PubMed ID: 19359030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
